X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PIRAMAL ENTERPRISES ALEMBIC PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 28.7 36.7 78.3% View Chart
P/BV x 6.6 3.1 214.8% View Chart
Dividend Yield % 0.7 0.8 90.1%  

Financials

 ALEMBIC PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
PIRAMAL ENTERPRISES
Mar-17
ALEMBIC PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs7922,095 37.8%   
Low Rs4431,025 43.2%   
Sales per share (Unadj.) Rs167.0492.8 33.9%  
Earnings per share (Unadj.) Rs38.272.6 52.6%  
Cash flow per share (Unadj.) Rs42.094.7 44.4%  
Dividends per share (Unadj.) Rs4.0021.00 19.0%  
Dividend yield (eoy) %0.61.3 48.1%  
Book value per share (Unadj.) Rs84.9862.5 9.8%  
Shares outstanding (eoy) m188.52172.56 109.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.2 116.8%   
Avg P/E ratio x16.221.5 75.2%  
P/CF ratio (eoy) x14.716.5 89.2%  
Price / Book Value ratio x7.31.8 402.0%  
Dividend payout %10.528.9 36.2%   
Avg Mkt Cap Rs m116,383269,194 43.2%   
No. of employees `000NA4.0 0.0%   
Total wages/salary Rs m4,21417,939 23.5%   
Avg. sales/employee Rs ThNM21,190.3-  
Avg. wages/employee Rs ThNM4,470.1-  
Avg. net profit/employee Rs ThNM3,120.0-  
INCOME DATA
Net Sales Rs m31,48785,037 37.0%  
Other income Rs m552,338 2.4%   
Total revenues Rs m31,54287,374 36.1%   
Gross profit Rs m10,06034,991 28.7%  
Depreciation Rs m7223,817 18.9%   
Interest Rs m3720,310 0.2%   
Profit before tax Rs m9,35613,202 70.9%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m2,1602,281 94.7%   
Profit after tax Rs m7,19412,520 57.5%  
Gross profit margin %31.941.1 77.6%  
Effective tax rate %23.117.3 133.6%   
Net profit margin %22.814.7 155.2%  
BALANCE SHEET DATA
Current assets Rs m15,06687,590 17.2%   
Current liabilities Rs m7,674185,578 4.1%   
Net working cap to sales %23.5-115.2 -20.4%  
Current ratio x2.00.5 415.9%  
Inventory Days Days6731 215.7%  
Debtors Days Days4148 85.4%  
Net fixed assets Rs m8,237108,523 7.6%   
Share capital Rs m377345 109.2%   
"Free" reserves Rs m15,416148,481 10.4%   
Net worth Rs m16,005148,826 10.8%   
Long term debt Rs m0144,957 0.0%   
Total assets Rs m24,594482,394 5.1%  
Interest coverage x255.21.7 15,468.7%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.30.2 726.3%   
Return on assets %29.46.8 432.0%  
Return on equity %44.98.4 534.3%  
Return on capital %58.712.0 490.9%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283NA-   
Fx inflow Rs m17,81115,001 118.7%   
Fx outflow Rs m5,3185,150 103.3%   
Net fx Rs m12,4939,851 126.8%   
CASH FLOW
From Operations Rs m9,304-100,393 -9.3%  
From Investments Rs m-3,105-24,202 12.8%  
From Financial Activity Rs m-1,959135,705 -1.4%  
Net Cashflow Rs m4,24011,110 38.2%  

Share Holding

Indian Promoters % 74.1 52.9 140.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 4.0 72.5%  
FIIs % 9.1 26.6 34.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 16.5 84.2%  
Shareholders   49,328 93,274 52.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES SHASUN LTD  WYETH LTD  ASTRAZENECA PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS